Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 12/20 | 0.65 |
| ▸ | NOS3 | P29474 | 8/20 | 0.65 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.38 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | APEX1 | P27695 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.35 |
| ▸ | AGPAT2 | O15120 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5077795 | 0.84 | NOS1 (0.71) | NOS1NOS3CYP1A1CYP1B1NOS2 | |
| SCHEMBL5776507 | 0.82 | NOS1 (0.68) | NOS1NOS3CYP1A1CYP1B1NOS2 | |
| SCHEMBL8275765 | 0.81 | NOS1 (0.69) | NOS1NOS3CYP1A1CYP1B1NOS2 | |
| SCHEMBL194469 | 0.79 | NOS1 (1.00) | NOS1NOS3CYP1A1CYP1B1NOS2 | |
| SCHEMBL8276020 | 0.79 | NOS1 (0.71) | NOS1NOS3 | |
| SCHEMBL8275750 | 0.79 | NOS1 (0.67) | NOS1NOS3CYP1A1CYP1B1NOS2 | |
| SCHEMBL6713816 | 0.77 | NOS1 (1.00) | NOS1NOS3NOS2 | |
| SCHEMBL8275801 | 0.77 | NOS1 (0.68) | NOS1NOS3NOS2ALDH1A1LMNA | |
| SCHEMBL8275994 | 0.77 | NOS1 (0.69) | NOS1NOS3CYP1A1CYP1B1NOS2 | |
| SCHEMBL8275718 | 0.77 | NOS1 (0.64) | NOS1NOS3CYP1A1CYP1B1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1434624-B1 | 2-AMINO-6-(2,4,5-SUBSTITUTED-PHENYL)-PYRIDINES FOR USE AS NITRIC OXIDE SYNTHASE INHIBITORS | PFIZER PROD INC (US) | 2006-11-02 | — | — | EP | claimed |
| US-20050032847-A1 | 2-amino-6(2,4,5-substitued-phenyl)-pyridines | PFIZER INC. | 2005-02-10 | — | — | US | claimed |
| US-6803470-B2 | NITRIC OXIDE SYNTHASE INHIBITORS. | PFIZER INC | 2004-10-12 | — | — | US | claimed |
| EP-1434624-A1 | 2-AMINO-6-(2,4,5-SUBSTITUTED-PHENYL)-PYRIDINES FOR USE AS NITRIC OXIDE SYNTHASE INHIBITORS | Pfizer Products Inc. (US) | 2004-07-07 | — | — | EP | claimed |
| US-20030087891-A1 | 2-Amino-6-(2,4,5-substituted-phenyl)-pyridines | PFIZER INC. | 2003-05-08 | — | — | US | claimed |
| WO-2003030993-A1 | 2-AMINO-6-(2,4,5-SUBSTITUTED-PHENYL)-PYRIDINES FOR USE AS NITRIC OXIDE SYNTHASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2003-04-17 | — | — | WO | claimed |
| US-20080070952-A1 | Inhibition or Treatment of Dyskinesia | PROXIMAGEN LTD., (GB) | 2008-03-20 | — | — | US | disclosed |
| EP-1434624-B1 | 2-AMINO-6-(2,4,5-SUBSTITUTED-PHENYL)-PYRIDINES FOR USE AS NITRIC OXIDE SYNTHASE INHIBITORS | PFIZER PROD INC (US) | 2006-11-02 | — | — | EP | disclosed |
| US-20060058267-A1 | Pharmaceutical compositions comprising a NOS inhibitor | PFIZER INC | 2006-03-16 | — | — | US | disclosed |
| EP-1596861-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A NOS INHIBITOR AND AN NMDA RECEPTOR ANTAGONIST | Pfizer Products Inc. (US) | 2005-11-23 | — | — | EP | disclosed |
| US-20050032847-A1 | 2-amino-6(2,4,5-substitued-phenyl)-pyridines | PFIZER INC. | 2005-02-10 | — | — | US | disclosed |
| US-20050032847-A1 | 2-amino-6(2,4,5-substitued-phenyl)-pyridines | PFIZER INC. | 2005-02-10 | — | — | US | disclosed |
| US-6803470-B2 | NITRIC OXIDE SYNTHASE INHIBITORS. | PFIZER INC | 2004-10-12 | — | — | US | disclosed |
| US-6803470-B2 | NITRIC OXIDE SYNTHASE INHIBITORS. | PFIZER INC | 2004-10-12 | — | — | US | disclosed |
| WO-2004073712-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A NOS INHIBITOR AND AN NMDA RECEPTOR ANTAGONIST | PFIZER PRODUCTS INC. (US) | 2004-09-02 | — | — | WO | disclosed |
| EP-1434624-A1 | 2-AMINO-6-(2,4,5-SUBSTITUTED-PHENYL)-PYRIDINES FOR USE AS NITRIC OXIDE SYNTHASE INHIBITORS | Pfizer Products Inc. (US) | 2004-07-07 | — | — | EP | disclosed |
| US-20040077853-A1 | 2-amino-6-(2,4,5-substituted-phenyl)-pyridines | PFIZER INC. | 2004-04-22 | — | — | US | disclosed |
| US-20030087891-A1 | 2-Amino-6-(2,4,5-substituted-phenyl)-pyridines | PFIZER INC. | 2003-05-08 | — | — | US | disclosed |
| US-20030087891-A1 | 2-Amino-6-(2,4,5-substituted-phenyl)-pyridines | PFIZER INC. | 2003-05-08 | — | — | US | disclosed |
| WO-2003030993-A1 | 2-AMINO-6-(2,4,5-SUBSTITUTED-PHENYL)-PYRIDINES FOR USE AS NITRIC OXIDE SYNTHASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2003-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058267-A1 | Pharmaceutical compositions comprising a NOS inhibitor | NOS1, NOS2, NOS3 | NOS1 1/4885NOS3 3/4885CYP1A1 365/4885 |
| US-20080070952-A1 | Inhibition or Treatment of Dyskinesia | DBH, COMT, DDO | NOS1 15/4885NOS3 18/4885CYP1A1 1849/4885 |
| US-20030087891-A1 | 2-Amino-6-(2,4,5-substituted-phenyl)-pyridines | PNMT, HTR6, HTR2C | NOS1 2251/4885NOS3 1089/4885CYP1A1 562/4885 |
| US-20040077853-A1 | 2-amino-6-(2,4,5-substituted-phenyl)-pyridines | NOS3, NOS1, NOS2 | NOS1 2/4885NOS3 1/4885CYP1A1 77/4885 |
| US-20050032847-A1 | 2-amino-6(2,4,5-substitued-phenyl)-pyridines | PNMT, HTR6, HTR2C | NOS1 2336/4885NOS3 1069/4885CYP1A1 447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.